Efficacy of ceftaroline in the therapy of respiratory infections

The growing resistance of infectious agents to antimicrobial drugs (AMDs) is an important issue in antimicrobial therapy. The rate of emergence of new antibiotics against the background of the development and reproduction of resistant microorganisms is in stagnation. Ceftaroline, one of the AMD representatives, has valuable properties, which, among other things, distinguish it from other antibiotics. It is especially valuable for its activity against the main causative agent of the skin and soft tissue infection S. aureus (MRSA). It also exhibits activity against penicillin-, macrolide- and fluoroquinolone-resistant pneumococci, as well as Haemophilus influenzae strains that produce beta-lactamases, and provides opportunities for the treatment of respiratory infections.